Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. (linkinghub.elsevier.com)

Authors: Silverberg JI … Warren RB Journal: The Lancet Published: 2026-08-21 DOI: https://doi.org/10.1016/S0140-6736(26)01143-8